Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL Therapy and Peginterferon for Metastatic Melanoma
NCT02379195Phase 2Completed
- Start
- Nov 2014
- Primary completion
- Jan 2018
- Modality
- Polymer-based Nanoparticles, Cell Therapies, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of therapeutic tumor-infiltrating lymphocytes and peginterferon alfa-2b in melanoma. Primary endpoint: Adverse Events and Serious Adverse Events at 24 weeks. Started Nov 2014; status: completed.
02
Drugs
therapeutic tumor-infiltrating lymphocytespeginterferon alfa-2b
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02379195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02379195.